Treatment of mucocutaneous presentations of herpes simplex virus infections.
Infections by herpes simplex virus (HSV) types I and II are diverse and quite frequent. After primary infection, the virus establishes a life-long latency in the sensory ganglia and recrudescences may occur at an unpredictable rate. Recurrent labial and genital herpes infections represent the majority of clinical manifestations of HSV infections. Their management is currently well established using evidence-based medicine data. Primary labial herpes is generally not treated with antivirals in otherwise healthy children, although intravenous aciclovir may be offered in severe primary infections, particularly in the immunocompromised patient. The decision whether or not to treat recurrent labial herpes should be evaluated individually and depends on the frequency and severity of relapses, the impairment of the quality of life, and the cost of therapy. Patients with mild disease may benefit from topical therapy, and those with severe and frequent recurrences may be considered for intermittent or long-term oral antiviral therapy. Primary genital herpes is treated with oral or intravenous antivirals, depending on the severity of the infection and associated symptoms. Recurrent genital herpes can be managed with episodic short courses of oral antivirals in patients whose recurrences are moderate to severe and rare, and have a clear prodrome. Patients with >5 episodes/year, severe recurrences or unrecognisable prodromes may be best managed with long-term suppressive antiviral prophylaxis. HSV is also responsible for a variety of other clinical manifestations, including herpetic whitlow, neonatal infection, disseminated and atypical cutaneous infections, traumatic herpes, eczema herpeticum, and HSV-associated erythema multiforme. HSV infection may also represent a complication following cosmetic procedures of the oro-facial region, surgical and dental interventions, sun exposure and burns. Precise treatment guidelines for these HSV infections are not firmly established.
Nikkels
Arjen F
AF
Department of Dermatopathology, University Medical Center of Liege, Liege, Belgium. A.F.Nikkels@chu.ulg.ac.be
Pièrard
Gérald E
GE
D000051:Acantholysis / Q000188:drug therapy; D000998:Antiviral Agents / Q000627:therapeutic use*; D002056:Burns / Q000150:complications; D004892:Erythema Multiforme / Q000821:virology; D006558:Herpes Genitalis / Q000188:drug therapy; D006560:Herpes Labialis / Q000188:drug therapy; D006561:Herpes Simplex / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy; D011183:Postoperative Complications; D012008:Recurrence; D012867:Skin / Q000293:injuries; D014466:Ultraviolet Rays / Q000009:adverse effects
D000998:Antiviral Agents